Mineralys Therapeutics, Inc. (MLYS)

USD 11.64

(-5.75%)

Market Cap (In USD)

579.3 Million

Revenue (In USD)

-

Net Income (In USD)

-71.89 Million

Avg. Volume

213.82 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.29-16.905
PE
-
EPS
-
Beta Value
2.4569244
ISIN
US6031701013
CUSIP
603170101
CIK
1933414
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jon Congleton
Employee Count
-
Website
https://mineralystx.com
Ipo Date
2023-02-10
Details
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.